Experts in TLR Biology

We are developing immunotherapies based on cutting-edge Toll-like receptor (TLR) biology and its ability to modulate the immune system. Learn More >

Cancer Immunotherapy

Through our expertise in TLR biology we are developing compounds designed to stimulate multiple innate mechanisms of tumor killing and development of immune memory associated with tumor-specific antigens. Learn More >

‹ ›

Cancer Immunotherapy

Utilizing Toll-like Receptor biology to leverage the power of the body's immune response to stimulate multiple innate mechanisms, activating a cascade of anti-tumor activities.

Learn More ›

Hepatitis B Vaccine

HBsAg-1018 is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with 1018, our proprietary TLR9 agonist.

Learn More ›

News

Jun02

Dynavax Presents Updated Data for SD-101 in Combination with KEYTRUDA(R) (pembrolizumab) Highlighting an ORR in 7 out of 7 Patients Naive to an Anti-PD-1 or Anti-PD-L1 Therapy

May19

Dynavax to Present Data on SD-101 in Combination with KEYTRUDA(R) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting

May08

Dynavax Reports First Quarter 2017 Financial Results

View All News

Our values

At Dynavax we are proud of the work we do. Our corporate values provide the foundation of our culture and how we operate as a company.

Learn More ›